Analyst Michael Cherny of Leerink Partners reiterated a Hold rating on DENTSPLY SIRONA, retaining the price target of $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Cherny has given his Hold rating due to a combination of factors impacting DENTSPLY SIRONA. The company is undergoing significant changes, including the appointment of a new CEO, Dan Scavilla, who brings extensive experience in the medtech industry. While Scavilla’s background and previous board membership may facilitate a smoother transition, there are still numerous challenges and uncertainties that need to be addressed before a more optimistic outlook can be justified.
Despite some signs of stability in the company’s recent quarterly results, such as earnings per share aligning with expectations, revenue projections fell short of some estimates. This mixed performance, coupled with ongoing efforts to innovate and improve cost efficiency, suggests that while the company is making strides, it is not yet in a position to warrant a more favorable rating. Therefore, maintaining a Hold rating reflects the need for further clarity and progress in the company’s strategic initiatives.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $15.50 price target.
XRAY’s price has also changed moderately for the past six months – from $18.960 to $15.630, which is a -17.56% drop .